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Abstract
Background and Aims
Nodular regenerative hyperplasia (NRH) of the liver is associated with several diseases and
drugs. Clinical symptoms of NRHmay vary from absence of symptoms to full-blown (non-
cirrhotic) portal hypertension. However, diagnosing NRH is challenging. The objective of
this study was to determine inter- and intraobserver agreement on the histopathologic diag-
nosis of NRH.
Methods
Liver specimens (n=48) previously diagnosed as NRH, were reviewed for the presence of
NRH by seven pathologists without prior knowledge of the original diagnosis or clinical
background. The majority of the liver specimens were from thiopurine using inflammatory
bowel disease patients. Histopathologic features contributing to NRH were also assessed.
Criteria for NRH were modified by consensus and subsequently validated. Interobserver
agreement was evaluated by using the standard kappa index.
Results
After review, definite NRH, inconclusive NRH and no NRH were found in 35% (23-40%),
21% (13-27%) and 44% (38-56%), respectively (median, IQR). The median interobserver
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agreement for NRH was poor (κ = 0.20, IQR 0.14-0.28). The intraobserver variability on
NRH ranged between 14% and 71%. After modification of the criteria and exclusion of biop-
sies with technical shortcomings, the interobserver agreement on the diagnosis NRH was
fair (κ = 0.45).
Conclusions
The interobserver agreement on the histopathologic diagnosis of NRH was poor, even
when assessed by well-experienced liver pathologists. Modification of the criteria of NRH
based on consensus effort and exclusion of biopsies of poor quality led to a fairly increased
interobserver agreement. The main conclusion of this study is that NRH is a clinicopatholog-
ic diagnosis that cannot reliably be based on histopathology alone.
Introduction
Nodular regenerative hyperplasia (NRH) is a vascular disorder of the liver which is increasingly
recognized in daily clinical practice. The occurrence of NRH is associated with certain diseases,
including immune mediated disorders, such as inflammatory bowel disease (IBD). Nodular Re-
generative Hyperplasia in HIV-infected patients seems strongly associated with the cumulative
exposure to didanosine and stavudine, anti-retroviral drugs causing toxic injury to sinusoidal
endothelial cells. [1–8]
Nodular Regenerative Hyperplasia has been reported to be an underrated adverse event of
thiopurine use, widely prescribed in IBD patients. [6–10] The clinical manifestation of NRH
consists of symptoms of non-cirrhotic portal hypertension, such as splenomegaly, thrombocy-
topenia and oesophageal varices. [11,12] NRH is allegedly associated with the development of
hepatocellular carcinoma. [13]
Although mostly referred to as a clinical disease entity, NRH is actually a histopathologic
feature that generally coincides with other histopathologic features indicative of vascular liver
toxicity such as phlebosclerosis (obliterative portal venopathy), sinusoidal dilatation, sinusoidal
obstruction syndrome, centrilobular venopathy and perisinusoidal fibrosis. [12,14]
The clinical significance of a histopathologic diagnosis of NRH is yet unclear, as NRH asso-
ciated symptoms are diverging from absence of symptoms or mild liver test abnormalities, up
to severe complications such as portal hypertension. [6,7]
The temporal relation between development of histopathologic NRH and clinical signs of
portal hypertension is not yet elucidated. Whether non-cirrhotic portal hypertension is the
obligatory clinical end-stage in all patients diagnosed with NRH or only in a subset has not
been established either. [15,16]
The discussion concerning the histopathologic diagnosis of NRH was revived due to its as-
sociation with tioguanine and conventional thiopurine use in IBD patients. [6–8,17] Based on
this association, the ongoing clinical use of thiopurines, in particular tioguanine, has been
strongly discouraged ever since.
However, the diagnosis of NRHmay be challenging due to different interpretations of specif-
ic histopathologic features by pathologists. Therefore, in 1990, Wanless redefined the definition
of NRH as part of a new classification of micronodular transformation. [18] These criteria have
never been validated. The primary objective of this study was to calculate the inter- and intraob-
server agreement for the histopathologic diagnosis of NRH and the specific characteristics that
contribute to this diagnosis, focusing on patients with IBD who were treated with thiopurines.
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Material and Methods
Study design
From six different European third-line referral hospitals (Munich, Vienna, Rotterdam, Paris,
Lille and Amsterdam), 48 liver biopsy specimens previously diagnosed solely as NRH were col-
lected. Thirty-six liver specimens were obtained from IBD patients who had been using azathi-
oprine, mercaptopurine or tioguanine. Twelve liver biopsies came from non-IBD patients who
had no (previous) exposure to thiopurines (Fig 1).
Thirty-four out of the 36 specimens that were obtained from thiopurine exposed IBD pa-
tients were previously reported in three studies that addressed the safety of either azathioprine
or tioguanine treatment in IBD. [7,19,20] All liver specimens were individually reviewed by
seven experienced liver pathologists, six of whom were affiliated with the hospital where the bi-
opsy specimens were obtained. The pathologists were not provided with clinical information
nor were they aware that only biopsy specimens previously diagnosed as NRH were included
in the review process. Five out of seven pathologists additionally scored specific histologic fea-
tures that contribute to the histopathologic diagnosis of NRH including characteristics of
nodularity and fibrosis. Two pathologists also assessed the quality of the biopsy specimens.
After independent examination of the liver slides, all pathologists attended a meeting held
at the VU University Medical Center in Amsterdam, the Netherlands, to develop an updated
consensus on the existing histopathologic diagnosis of NRH and its specific features. Liver
slides were collectively reviewed to provide a definitive and unanimous diagnosis, being used
as the histopathologic gold standard for validation of the consensus. The updated histologic
criteria from the consensus meeting were independently validated by two experienced liver pa-
thologists, who were not involved in the earlier consensus meeting.
Ethical considerations
The liver specimens that were not obtained in the Netherlands and were primarily obtained
for the purpose of other studies, were obtained after written informed consent in the two
studies reporting on the use of tioguanine. [19,20] The biopsy specimens from the third
study, obtained in an azathioprine using cohort, as well as the remaining liver specimens in-
cluded in this study were performed as part of standard care; verbal consent was obtained.
[7] All liver specimens were sent to Amsterdam without any identifying information. As
Fig 1. Origin of liver specimens with Nodular Regenerative Hyperplasia (NRH).
doi:10.1371/journal.pone.0120299.g001
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patients included in this study were not subjected to additional tests or questionnaires no of-
ficial ethical approval was required according to the Dutch Medical Research Involving
Human Subjects Act. According to the Dutch code of conduct for dealing responsibly with
human tissue in the context of health research, all specimens and clinical data used in this
study were coded anonymous.
Liver biopsy specimen
Liver specimens were obtained by percutaneous needle biopsy or by surgical wedge resection
during a surgical procedure indicated for the treatment of IBD. All specimens had been stained
with hematoxylin & eosin (H&E), reticulin and at least one collagen stain (Masson’s trichrome,
Sirius red stain or Elastica von Giesson stain). The quality of liver specimens was assessed by
evaluating total biopsy length, the number of portal tracts and whether the biopsy specimen
was fragmented.
Study outcome
The primary outcome of the study was to evaluate inter- and intraobserver agreement on the
diagnosis of NRH. All pathologists were familiar with the criteria for NRH as proposed by
Wanless: NRH was present if nodularity was distinct in most areas examined in both the H&E
and reticulin staining (Grade 3). Septal fibrosis had to be either absent (Grade 0), or only occa-
sionally present but not surrounding the nodules (Grade 1) to be compatible with NRH. [17]
In this study, the presence of NRH was subsequently scored as: definite NRH, no NRH or in-
conclusive NRH if the pathologists believed that technical shortcomings hampered a
proper evaluation.
Five out of seven pathologists assessed specific histopathologic features that characterize
NRH. These features included the presence of hepatocellular nodules< 3mm, regions of hy-
perplasia with a curved contour, regions of atrophy surrounding the regions of hyperplasia,
liver cell plates> 1 cell layer thick producing a compression zones at the periphery of nodules
and (the absence of) septal fibrosis.
Statistical analysis
Continuous variables were expressed as the median with interquartile range (IQR). Categorical
variables were expressed as numbers and percentages. Intraobserver variation was calculated as
the percentage of NRH diagnosed by each pathologist compared with the original 100 percent
score on biopsies assessed by the same pathologist. The interobserver agreement was evaluated
by calculating the kappa index (κ), which excludes chance-expected agreement. The kappa
could range from<0.4 = poor; 0.4–0.75 = fair to good;>0.75 = excellent. Kappa values were
calculated for comparisons between each pair of pathologists. The overall interobserver agree-
ment kappa between all pathologists was calculated for NRH and the specific features of NRH.
To evaluate the potential influence of the quality of specimens, a sub-analysis with regard to in-
terobserver agreement was made by selecting high quality liver slides (i.e. larger than 10mm
and without technical shortcomings).
The observer bias was also investigated. [21] An observer bias means that disagreement be-
tween observers is not attributable to chance, and that there is a significant trend for overesti-
mation or underestimation by certain observers. A p-value less than 0.05 was considered to be
statistically significant. Statistical analysis was performed using the Statistical Package for the
Social Sciences version 16.0, Chicago, USA.
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Results
Biopsy specimens and patient characteristics
Forty-eight liver specimens were examined in this study. Indications for liver biopsy were signs
of portal hypertension and/or biochemical liver abnormalities, use of tioguanine or unknown
in respectively 46%, 42% and 13%. Biopsy specimens had a median length of 20 mm (IQR 13–
26 mm). A significant part of patients suffered from signs not specifically for, but indicative of,
portal hypertension such as oesophageal varices, thrombocytopenia, splenomegaly, hepatofu-
gal flow and ascites (Table 1).
Re-assessment of the biopsy specimens resulted in large intra- and interobserver differences.
The intraobserver agreement on definite NRH ranged between 14% and 71%, with a median of
67% (Table 2).
Table 1. Patient characteristics including clinical symptoms of portal hypertension.
Total number of liver specimens = 48
IBD/ non-IBD 36/ 12
Thiopurines/ no Thiopurines 36/ 12
Thiopurines (n = 36)
Azathioprine (median dosage) 15 (2 mg/kg/day, IQR 2.0–2.25)
Mercaptopurine 1 (1 mg/kg/day)
Tioguanine (median dosage) 20 (40 mg/day, IQR 40–40)
Portal hypertension (endoscopy and/or liver imaging) Percentage
Hepatofugal flow 24% (9/37)
Splenomegaly 31% (13/42)
Collaterals 17% (7/42)
Ascites 7% (3/41)
Oesophageal varices 44% (14/32)
Any of above mentioned symptoms
50% (21/42)
IBD, inflammatory bowel disease.
Poor intra- and interobserver agreement on the diagnosis of NRH and its specific histopathologic criteria.
doi:10.1371/journal.pone.0120299.t001
Table 2. Intra and inter observer variability of nodular regenerative hyperplasia.
Pathologist 1 2 3 4 5 6 7
1 67% 0% 0% 67% 67% 33% 100%
2 64% 64% 18% 46% 55% 27% 55%
3 14% 7% 14% 14% 14% 7% 14%
4 50% 0% 0% 67% 0% 33% 33%
5 29% 43% 0% 29% 71% 71% 43%
6 29% 0% 29% 29% 57% 71% 43%
Intraobserver (bold, italic cells) and interobserver variability in the diagnosis of NRH after re-assessment of liver slides by seven pathologists. Six
pathologists from six hospitals provided liver slides that had originally been diagnosed as NRH. Pathologist 1 corresponds with pathologist 1, etc.
Pathologist 7 did not provide liver slides for this study.
doi:10.1371/journal.pone.0120299.t002
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Between pathologists, variation in the diagnosis of definite NRH ranged from 13% to 40%,
with a median of 35%. Diagnosis of inconclusive NRH, and no NRH ranged from 13% to 40%
(median 21%) and 21% to 75% (median 44%), respectively (Table 3).
Some pathologists did not observe any NRH in the liver slides provided by other medical in-
stitutes. The median interobserver agreement for the histopathologic diagnosis of NRH, scored
by all seven pathologists, was poor (κ = 0.20, IQR 0.14–0.28). The intra-observer agreement of
one of the pathologists was very low (14%). After exlusion of this pathologist, inter-observer
agreement for NRH remained poor (κ = 0.23, IQR 0.15–0.30).
The median interobserver agreement for definite NRH was not statistically significant dif-
ferent between IBD and non-IBD patients. Twenty-four out of 48 (50%) liver biopsies, includ-
ing all surgical wedge resections (n = 5), were arbitrarily considered adequate for proper
evaluation as these liver biopsies were more than 10 mm in length and were not fragmented.
Interobserver agreement, however, remained similar with restricted use of only these adequate
liver specimens (data not shown).
Five pathologists additionally assessed the specific histolopathologic features of NRH. The
median interobserver agreement for characteristics of NRH were 0.31 for hepatocellular
nodules< 3mm (IQR 0.17–0.38), 0.17 for regions of hyperplasia (IQR 0.06–0.22), 0.25 for re-
gions of atrophy (IQR 0.20–0.34), 0.11 for compression zones (IQR 0.06–0.35) and 0.49 for ab-
sence of septal fibrosis (IQR 0.41–0.58).
Consensus view on the specific characteristics of NRH and proposed
modified definition
Collective reassessment of liver slides by the participating pathologists resulted in a slight mod-
ification of the histopathologic definition of NRH as proposed by Wanless in 1990. [18] This
adapted consensus view on the diagnosis of NRH did acknowledge that for a histopathologic
diagnosis of NRH the presence of grade 3 micronodularity (distinct nodularity in both H&E
and reticulin staining) was mandatory. In contrast to Wanless’ definition in which grade 1 sep-
tal fibrosis was accepted, the consensus view was that any septal fibrosis excluded a diagnosis
of NRH. The recognition of (non-septal) perisinusoidal fibrosis, however, was added and was
found to be compatible with NRH. In addition, a description of the extent of nodularity (i.e.
focal or diffuse) complemented the description of the biopsy. In case of severe steatosis (more
than 2/3 of liver biopsy) or steatohepatitis, the adapted consensus view was that NRH could
not be properly assessed. The quality of liver specimens was believed to be of great importance
for properly diagnosing NRH. Therefore, both specimen length and whether or not the speci-
men was fragmented should be specified. Despite technical shortcomings such as short length
and fragmentation, a histopathologic diagnosis of NRH can be made. However, it was believed
by consensus that technical shortcomings of a biopsy specimen could not exclude the presence
of NRH (Table 4).
These subtle changes to the definition of NRH led to the following description: nodular re-
generative hyperplasia of the liver is characterized by the focal or diffuse appearance of hepato-
cellular nodule(s) less than 3mm in diameter consisting of a central part of enlarged hepatocytes
Table 3. Diagnosis of nodular regenerative hyperplasia on re-examination of all 48 liver specimens.
Pathologist 1 2 3 4 5 6 7
Definite NRH 38% 23% 13% 35% 40% 35% 40%
Inconclusive NRH 19% 21% 13% 27% 40% 21% 13%
No NRH 44% 56% 75% 38% 21% 44% 48%
doi:10.1371/journal.pone.0120299.t003
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and/or thickened liver cell plates with a rim of smaller hepatocytes and/or thinner liver cell
plates with compression of the sinuses in the periphery where perisinusoidal but not septal fi-
brosis may occur. The nodules need to be distinct on both H&E and reticulin staining (Fig 2).
Portal hypertension in definite NRH, inconclusive NRH and no NRH
During the consensus meeting, 32/48 liver biopsies were collectively assessed and consensus
was reached. NRH, inconclusive NRH and no NRH were diagnosed in 7/32 (22%), 4/32 (13%)
and 21/32 (66%) liver biopsies, respectively. Portal hypertension was reported in 71%, 50% and
38% of the patients with respectively definite NRH, uncertain NRH and no NRH.
Calculation of observer agreement when using the modified definition of
NRH
The updated description of the consensus definition of NRH was used for validation by two in-
dependent liver pathologists, who did not participate in the earlier phases of this study. The up-
date of the definition of NRH resulted in a slight increase of the interobserver agreement
(kappa = 0.35), however this still remained poor. The interobserver agreement further im-
proved (kappa = 0.45) after exclusion of liver biopsies with technical shortcomings.
Discussion
This study showed that the interobserver agreement of NRH and specific histologic features of
NRH in properly stained liver biopsies was poor, even when assessed by well-experienced liver
pathologists. Moreover, large differences in intraobserver agreement were observed after reas-
sessment of liver slides, previously diagnosed with NRH. Refining existing criteria based on a
consensus effort led to only a marginal improvement.
The main strength of this study was its multi-center character involving a large group of
liver pathologists from all over Europe. Of importance, clinical data, such as that the majority
of the included liver specimens were from IBD patients on past or present thiopurine use, were
being withheld from the pathologists, aiming at unbiased (microscopy-based) scoring of the
liver biopsy specimens. Furthermore, there seemed no major role for a potential observer bias
as the intra- and interobserver agreements were poor even though all pathologists knew they
were participating in a study on NRH.
There are also some limitations of our study. First, although initially designed to calculate
interobserver agreement on an established diagnosis of NRH, the low agreement between and
within observers (pathologists) raised the question whether addition of a series of control biop-
sy specimens would have improved diagnostic accuracy. The ‘true” diagnostic accuracy of
Table 4. Description of criteria compatible with nodular regenerative hyperplasia (NRH) of the liver according to Wanless et al.[
18] versus Jharap
et al.
NRH Wanless et al.[18] Jharap et al.
Hepatocellular
nodules
Regions of atrophy juxtaposed to normal or
hyperplastic regions with a curved contour
Central part of enlarged hepatocytes and/or thickened liver cell plates with a rim
of smaller hepatocytes and/or thinner liver cell plates at the outer border of the
nodule with compression of the sinuses in the periphery
Fibrous septa Hepatocellular nodules are not surrounded by
fibrous septa
Hepatocellular nodules are not surrounded by fibrous septa
Perisinusoidal
fibrosis
Occasional septa not surrounding nodules is
compatible with NRH
Perisinusoidal or pericellular collagen fibrosis is compatible with NRH
Cell plates In NRH, hepatocytes are often arranged in
double-cell plates
In NRH, hepatocytes are often arranged in double-cell plates
doi:10.1371/journal.pone.0120299.t004
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histologic readings, measured by the traditional indices of sensitivity, specificity, positive and
negative predictive value cannot be determined from this study in the absence of both negative
controls and a gold standard for positive liver biopsies. In this regard however, it is essential to
mention that our study did not intend to assess diagnostic accuracy, but was designed instead
Fig 2. Histopathologic liver specimen with nodular regenerative hyperplasia. A. Hematoxylin & eosin
staining. B. Reticulin staining in which the nodules are apparent. C. Sirius red staining highlighting the subtle
collagen fibres around the atrophic liver cell plates.
doi:10.1371/journal.pone.0120299.g002
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to explore inter- and intraobserver agreements, neither of which by definition requires control
groups nor gold standard criteria for positive liver biopsies. Until now, the diagnosis of NRH
was based on criteria described by Wanless, even though these criteria have never been validat-
ed. [18] Our study demonstrated that the variability of the histologic diagnosis of NRH, based
on the Wanless criteria, is high, therefore a gold standard for NRH does not exist, i.e. a positive
control group is not possible. In addition, the aim of the study focused on the reproducibility of
the histologic diagnosis of NRH. A negative control group was not added, as it is very challeng-
ing to define a negative control group, as several studies have shown that there is already a sig-
nificant interobserver variability in assessment of liver biopsies with regard to other diagnoses
besides NRH. [22]
Secondly, the quality of several biopsies used in this study was scored as being of suboptimal
quality for microscopic examination. Approximately half of the biopsies were fragmented and
had a total length of less than 10mm. This, however, reflects day-by-day clinical practice both
regarding the harvest of liver biopsy specimens as well as the material which is provided to pa-
thologists to make a histopathologic diagnosis. Rousselet et al. showed that quality of the liver
biopsy may influence inter-observer agreement. [21] Nevertheless, the exclusion of small and
fragmented biopsies from our study only led to a marginal increase in interobserver agreement
from 0.35 to 0.45. This discrepancy may be due to small sample size.
Finally, this study was only designed to specifically address the histopathologic diagnosis of
NRH. The participating pathologists were not aware of the clinical background of the patients
when they reviewed the liver slides; therefore there was no bias during re-assessment of the
liver slides. However, the majority of patients had a history of thiopurine use, which may have
caused patient selection bias. From a more clinical perspective, it would have been of additional
interest to explore other histopathologic features, such as sinusoidal dilatation, dilated portal
veins (shunt vessels), phlebosclerosis, centrilobular fibrosis, portal tract remnants and perisinu-
soidal fibrosis, which are also associated with idiopathic non-cirrhotic portal hypertension.
[3,12,23] This may be considered as a limitation.
The reasons for the observed low inter-observer agreement on the histopathologic diagnosis
of NRH even after modification of its definition are uncertain. It is fair to mention that follow-
ing the consensus, the definition of NRH was only slightly modified as compared to the defini-
tion of Wanless. [18] Hence, this definition can still be subject to different interpretation.
There are several possibilities for improvement of the poor inter-observer agreement of NRH.
It has been shown that education or consensus reading may result in improvement of inter-ob-
server agreement. [21] Although the involved pathologists used the updated description of the
consensus definition for NRH during validation, the kappa of NRH didn’t improve significant-
ly, indicating that consensus reading for the diagnosis NRH is not sufficient enough, and pa-
thologists need to be educated in the updated criteria for NRH. Rousselet et al. showed that
quality of the liver biopsy, such as length may influence inter-observer agreement. [21] Our
study didn’t demonstrate improvement of the kappa for NRH after exclusion of inadequate
liver biopsies, which may be explained by small sample size. Although the lack of clinical infor-
mation may have resulted in unbiased scoring of liver biopsies, it could also explain the re-
markable discrepancy between the proportion of NRH diagnosed at the original examination
when clinical data were available, and the lower proportion of NRH after reassessment of the
same liver biopsies, when patient characteristics were not provided. Unfortunately, our study
didn’t investigate the influence of clinical data or pathologists’ experiences and training on the
interobserver agreement. Future studies are needed to demonstrate whether adding clinical in-
formation improves inter-observer agreement.
Additionally, the diagnosis of NRH is not always obvious at liver biopsy and NRH can pres-
ent itself in different histologic grades. However, the diagnosis NRH is highly likely, when
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histologic criteria of NRH are present in a liver biopsy of a patient using NRH-associated drugs
and presenting himself with clinical signs of non-cirrhotic portal hypertension. Interpretation
of literature regarding prevalence or incident cases of drug or disease induced NRH appears to
be thwarted by the incongruence between histopathology and clinical syndrome as well. Ideally
non-invasive diagnostic tests would replace the liver biopsy in the future. Efforts have been
made to diagnose NRH by MRI and by measuring liver stiffness. Unfortunately, these diagnos-
tic modalities did not have enough diagnostic accuracy. [24,25]
In conclusion, the diagnosis of NRH based on histopathology alone is unreliable. In case of
discrepancy between clinical findings and histology, reports on the prevalence of NRH should
be interpreted with caution. For the moment, our study stresses the importance of close collab-
oration between the clinician and the pathologist before drawing definitive clinical conclusions
or taking any therapeutic decision solely based on the presence of NRH on a liver biopsy.
Acknowledgments
NRH-pathology Investigators:
Jacques Cosnes, Department of Gastroenterology and Nutrition, Saint-Antoine Hospital,
Paris, France
Carin M. J. van Nieuwkerk, Department of Gastroenterology and Hepatology, VU Universi-
ty Medical Center, Amsterdam, the Netherlands
Julia Seiderer, Department of Medicine II, Ludwig-Maximilians-University Munich,
Germany
Gwenola Vernier-Massouille, Department of Gastroenterology and Hepatology, CHRU
Lille, Lille, France
Author Contributions
Analyzed the data: BJ DA. Wrote the paper: BJ DA NB JFCWR CM EB AB. Designed the
study: NB AB. Revised the liver slides: BJ DA PB JD AMJ EL JV DW FW PZ EB. Contributed
liver specimens: AB JFC PZWR JD.
References
1. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created
equal. Hepatology 2006; 44: 7–14. PMID: 16799965
2. Núňez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology
2010; 52: 1143–55. doi: 10.1002/hep.23716 PMID: 20812358
3. Cotte L, Benet T, Billioud C. The role of nucleoside and nucleotide analogues in Nodular Regenerative
Hyperplasia in HIV-infected patients: a case control study. J Hepat 2011; 54 (3): 489–96
4. Rubbia-Brandt L, Lauwers GY,Wang H, Majno PE, Tanabe K, Zhu AX et al. Sinusoidal obstruction syn-
drome and nodular regenerative hyperplasia are frequent oxaliplatin associated liver lesions and par-
tially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010;
56: 430–9. doi: 10.1111/j.1365-2559.2010.03511.x PMID: 20459550
5. Force J, Saxena R, Schneider BP, Storniolo AM, Sledge GW Jr, Chalasani N et al. Nodular Regenera-
tive Hyperplasia after treatment with Trastuzumab Emtansine. J Clin Oncol. 2014 May 12; PMID:
24778392
6. DubinskyMC, Vasiliauskas EA, Singh H, AbreuMT, Papadakis KA, Tran T et al. 6-thioguanine can
cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125: 298–303.
PMID: 12891528
7. Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, ReinischW, Laharie D et al. Nodular regenera-
tive hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007; 56:
1404–9. PMID: 17504943
8. Seksik P, Mary JY, Beaugerie L, Lemann M, Colombel JF, Vernier-Massouille G et al. Incidence of nod-
ular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. Inflamm
Bowel Dis 2011; 17: 565–72. doi: 10.1002/ibd.21330 PMID: 20848502
NRH Is Thwarted by Low Interobserver Agreement
PLOS ONE | DOI:10.1371/journal.pone.0120299 June 8, 2015 10 / 11
9. Colombel JF, Sandborn WJ, ReinischW, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab,
azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362(15): 1383–95 doi:
10.1056/NEJMoa0904492 PMID: 20393175
10. Panaccione R, Ghosh S, Midleton S, Marquez JR, Scott BB, Flint L et al. Combination therapy with
infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroen-
terology 2014; 146(2): 392–400 PMID: 24512909
11. Morris JM, Oien KA, McMahon M, Forrest EH, Morris J, Stanley AJ et al. Nodular regenerative hyper-
plasia of the liver: survival and associated features in a UK case series. Eur J Gastroenterol Hepatol
2010; 22: 1001–5. doi: 10.1097/MEG.0b013e3283360021 PMID: 20075739
12. Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension.
Hepatology 2011; 54: 1071–81. doi: 10.1002/hep.24422 PMID: 21574171
13. Sood A, Cox GA 2nd, McWilliams JP, Wang HL, Saab S. Patients with nodular regenerative hyperpla-
sia should be considered for hepatocellular carcinoma screening. Hepatol Res 2014; 44(6): 689–93
doi: 10.1111/hepr.12136 PMID: 23607291
14. Rubbia-Brandt L. Sinusoidal obstruction syndrome. Clin Liver Dis 2010; 14: 651–68. doi: 10.1016/j.cld.
2010.07.009 PMID: 21055688
15. De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ et al. Histopathology
of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular re-
generative hyperplasia. Scand J Gastroenterol 2008; 43: 604–8. doi: 10.1080/00365520701800266
PMID: 18415755
16. Minervini MI, Ruppert K, Fontes P, Volpes R, Vizzini G, de Vera ME et al. Liver biopsy findings from
healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with
liver injury tests. J Hepatol 2009; 50: 501–10. doi: 10.1016/j.jhep.2008.10.030 PMID: 19155086
17. Teml A, Schwab M, Hommes DW, Almer S, Lukas M, Feichtenschlager T et al. A systematic survey
evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien Klin
Wochenschr 2007; 119(17–18): 519–26. PMID: 18043886
18. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64
cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology
1990; 11: 787–97. PMID: 2189821
19. Seiderer J, Zech CJ, ReinischW, Lukas M, Diebold J, Wrba F et al. A multicenter assessment of liver
toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 2005; 43: 303–9. PMID:
15964660
20. Ferlitsch A, Teml A, ReinischW, Ulbrich G, Wrba F, Homoncik M et al. 6-thioguanine associated nodu-
lar regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hyperten-
sion. Am J Gastroenterol 2007; 102: 2495–503. PMID: 17894846
21. Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP et al. Sources of variability in
histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257–64. PMID: 15660389
22. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases.
Journal of Hepatology 2007; 47 (4): 598–607 PMID: 17692984
23. Verheij J, Schouten JN, Komuta M, Nevens F, Hansen BE, Janssen HL et al. Histological features in
western patients with idiopathic non-cirrhotic portal hypertension. Histopathology 2013; 62: 1083–91.
doi: 10.1111/his.12114 PMID: 23600724
24. Zech CJ, Seiderer J, ReinischW, Ochsenkuhn T, SchimaW, Diebold J et al. Thioguanin-induced nodu-
lar regenerative hyperplasia of the liver—ROC analysis of different MR techniques. Eur Radiol 2007;
17: 1898–905. PMID: 17221208
25. Laharie D, Vergniol J, Bioulac-Sage P, Diris B, Poli J, Foucher J et al. Usefulness of noninvasive tests
in nodular regenerative hyperplasia of the liver. Eur J Gastroenterol Hepatol 2010; 22: 487–93. doi: 10.
1097/MEG.0b013e328334098f PMID: 19940782
NRH Is Thwarted by Low Interobserver Agreement
PLOS ONE | DOI:10.1371/journal.pone.0120299 June 8, 2015 11 / 11
